HK Stock Market Move | LIFETECH SCI(01302) Rises Nearly 5% in Afternoon; CSTM Stent System Enters Innovative Medical Management Special Inspection Program

LIFETECH SCI (01302) rose nearly 5% in the afternoon, up 3.66% as of the time of publication, at HK$1.7, with a trading volume of HK$57.7237 million. In terms of news, LIFETECH SCI announced that on January 9, 2026, the company received an official written notification from the National Medical Products Administration confirming that the Concave Supra integrated arch three-branch reconstruction system (CSTM stent system or the product) jointly developed by the National Cardiovascular Center of China Academy of Medical Sciences Fuwai Hospital Professor Shu Chang and the company has entered the National Medical Products Administration's Innovative Medical Management Device special review program. The product is suitable for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, and is the world's first brainless ischemia integrated arch three-branch reconstruction solution. This is the company's seventeenth product to enter the program of the National Medical Products Administration. The company owns the independent intellectual property rights of the product. Currently, the product has successfully completed multiple clinical implants in Germany, Switzerland, Greece, and Hong Kong, and its outstanding performance and clinical value have been highly recognized by international clinical experts. The company expects to have more abundant evidence-based medical evidence to further confirm the safety and effectiveness of the product. The Board of Directors believes that the product entering this program will shorten the product's registration process and accelerate its listing process.